SARS-CoV-2 Infection In Patients With Mastocytosis: An EPICOVIDEHA Report

• Authors: CRISCUOLO M.; SALMANTON-GARCIA J.; FRACCHIOLLA N.; DRAGONETTI G.; KHANNA N.; WEINBERGEROVÁ Barbora; SCHOENLEIN M.; MACHADO M.; LABRADOR J.; KOLDITZ M.; ITRI F.; GOMES Da Silva M.; BONUOMO V.; SCIUME M.; RODRIGUES R Nunes; GRAEFE S.; MARCHESI F.; CORNELY O. A.; PAGANO L.
• Year of publication: 2023
• Type: Article in Periodical
• Magazine / Source: Journal of Investigational Allergology and Clinical Immunology
• MU Faculty or unit: Faculty of Medicine
• Web: https://www.jiaci.org/summary/vol33-issue3-num2707
• Doi: http://dx.doi.org/10.18176/jiaci.0845
• Keywords: Systemic mastocytosis; SARS-CoV-2; COVID-19; Malignancy; Treatment
• Description: Systemic mastocytosis (SM) is a rare hematological disease characterized by neoplastic proliferation of clonal mast cells (MCs). It involves the gastrointestinal tract, bone, liver, and spleen in addition to bone marrow and skin. The symptoms caused by release of MC mediators and organ infiltration can seriously affect quality of life and survival. Patients with SM are not expected to have a higher risk of infection by SARS-CoV-2; however, this risk can be augmented by comorbidities and impairment of organ function due to infiltration by MCs. Treatment of SM is based on different classes of drugs, which may have an impact on outcome in SARS-CoV-2 infection. However, no study has reported the determinants of outcomes in patients with SM and SARS-CoV-2 infection, according to concurrent treatment.